Health Care & Life Sciences » Pharmaceuticals | Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
229,681.00
210,461.00
251,519.00
255,165.00
240,175.00
294,666
Cost of Goods Sold (COGS) incl. D&A
146,074.00
163,050.00
177,967.00
155,712.00
154,336.00
192,999
Gross Income
83,607.00
47,411.00
73,552.00
99,453.00
85,839.00
101,667
SG&A Expense
65,991.00
64,955.00
76,944.00
83,761.00
89,377.00
110,290
EBIT
17,616.00
17,544.00
3,392.00
-
3,538.00
8,623
Unusual Expense
126.00
439.00
3,506.00
-
-
-
Non Operating Income/Expense
508.00
201.00
2,794.00
8.00
5,562.00
1,516
Interest Expense
958.00
609.00
987.00
1,024.00
826.00
243
Pretax Income
17,227.00
18,148.00
10,364.00
14,946.00
1,623.00
9,926
Income Tax
5,365.00
7,449.00
7,577.00
4,414.00
2,885.00
3,266
Consolidated Net Income
11,862.00
10,699.00
2,787.00
10,532.00
4,508.00
6,660
Net Income
11,862.00
10,699.00
2,787.00
10,532.00
4,508.00
5,738
Net Income After Extraordinaries
11,862.00
10,699.00
2,787.00
10,532.00
4,508.00
5,738
Net Income Available to Common
11,862.00
10,699.00
2,787.00
10,532.00
4,508.00
5,738
EPS (Basic)
0.27
0.25
0.06
0.22
0.09
0.12
Basic Shares Outstanding
43,405.90
41,957.00
44,961.00
45,375.00
46,107.00
46,395
EPS (Diluted)
0.27
0.25
0.06
0.22
0.09
0.12
Diluted Shares Outstanding
43,405.90
41,957.00
44,961.00
47,504.00
48,367.00
46,395
EBITDA
30,694.00
3,096.00
9,860.00
30,256.00
11,898.00
7,893
Non-Operating Interest Income
187.00
243.00
315.00
270.00
425.00
456

About Amphastar Pharmaceuticals

View Profile
Address
11570 6th Street
Rancho Cucamonga California 91730
United States
Employees -
Website http://www.amphastar.com
Updated 07/08/2019
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.